

SEQUENCE LISTING

<110> Turk, Mary Jo
Guevara, Jose Alejandro
Houghton, Alan

<120> Liposomal System and Method of Using Same

<130> MSK.P-075

<150> US 60/416,194

<151> 2002-10-04

<160> 14

<170> PatentIn version 3.2

<210> 1

<211> 39

<212> PRT

<213> artificial

<220>

<223> fusion with Ova antigen and ubiquinating sequence

<400> 1

| | | | | | | | | | | | | | | | |
|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| Arg | Gly | Lys | Glu | Gln | Glu | Met | Ala | Thr | Ala | Ala | Ser | Ser | Gly | Lys | Lys |
| 1 | | | | 5 | | | | | 10 | | | | | 15 | |

| | | | | | | | | | | | | | | | |
|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| Lys | Gly | Gly | Gly | Leu | Glu | Gln | Leu | Glu | Ser | Ile | Ile | Asn | Phe | Glu | Lys |
| | | | 20 | | | | | 25 | | | | | 30 | | |

| | | | | | | |
|-----|-----|-----|-----|-----|-----|-----|
| Leu | Thr | Glu | Trp | Ser | Gly | Cys |
| | | | | | | 35 |

<210> 2

<211> 17

<212> PRT

<213> human

<400> 2

| | | | | | | | | | | | | | | | |
|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| Arg | Gly | Lys | Glu | Gln | Glu | Met | Ala | Thr | Ala | Ala | Ser | Ser | Gly | Lys | Lys |
| 1 | | | | 5 | | | | | 10 | | | | | 15 | |

Lys

<210> 3

<211> 8

<212> PRT

<213> artificial

<220>

<223> ovalbumin MHC-1 epitope

<400> 3

Ser Ile Ile Asn Phe Glu Lys Leu
1 5

<210> 4

<211> 20

<212> DNA

<213> artificial

<220>

<223> CpG containing sequence

<400> 4

tccatgacgt tcctgacgtt

20

<210> 5

<211> 16

<212> PRT

<213> artificial

<220>

<223> EWS/ATF1 breakpoint

<400> 5

Gly Gly Gly Arg Gly Gly Met Gly Lys Ile Leu Lys Asp Leu Ser Ser
1 5 10 15

<210> 6

<211> 36

<212> PRT

<213> artificial

<220>

<223> ubiquinatable peptide for EWS/ATF1 breakpoint

<400> 6

Arg Gly Lys Glu Gln Glu Met Ala Thr Ala Ala Ser Ser Gly Lys Lys
1 5 10 15

Lys Gly Gly Gly Gly Gly Gly Arg Gly Gly Met Gly Lys Ile Leu Lys
20 25 30

Asp Leu Ser Ser
35

<210> 7

<211> 16

<212> PRT

<213> artificial

<220>
 <223> SYT/SSX breakpoint
 <400> 7
 Gln Arg Pro Tyr Gly Tyr Asp Gln Ile Met Pro Lys Lys Pro Ala Glu
 1 5 10 15
 <210> 8
 <211> 36
 <212> PRT
 <213> artificial
 <220>
 <223> ubiquinatable peptide for SYT/SSX breakpoint
 <400> 8
 Arg Gly Lys Glu Gln Glu Met Ala Thr Ala Ala Ser Ser Gly Lys Lys
 1 5 10 15
 Lys Gly Gly Gly Gln Arg Pro Tyr Gly Tyr Asp Gln Ile Met Pro Lys
 20 25 30
 Lys Pro Ala Glu
 35
 <210> 9
 <211> 16
 <212> PRT
 <213> artificial
 <220>
 <223> TLS/CHOP breakpoint
 <400> 9
 Arg Gly Gly Phe Asn Lys Phe Gly Val Phe Lys Lys Glu Val Tyr Leu
 1 5 10 15
 <210> 10
 <211> 36
 <212> PRT
 <213> artificial
 <220>
 <223> ubuinatable peptide for TLS/CHOP breakpoint
 <400> 10
 Arg Gly Lys Glu Gln Glu Met Ala Thr Ala Ala Ser Ser Gly Lys Lys
 1 5 10 15

Lys Gly Gly Gly Arg Gly Gly Phe Asn Lys Phe Gly Val Phe Lys Lys
20 25 30

Glu Val Tyr Leu
35

<210> 11
<211> 16
<212> PRT
<213> artificial

<220>
<223> ASPL/TFE3 breakpoint

<400> 11

Gln Gln Glu Gln Glu Arg Glu Arg Leu Pro Val Ser Gly Asn Leu Leu
1 5 10 15

<210> 12
<211> 36
<212> PRT
<213> artificial

<220>
<223> ubiquinatable peptide for ASPL/TFE3 breakpoint

<400> 12

Arg Gly Lys Glu Gln Glu Met Ala Thr Ala Ala Ser Ser Gly Lys Lys
1 5 10 15

Lys Gly Gly Gly Gln Gln Glu Gln Glu Arg Glu Arg Leu Pro Val Ser
20 25 30

Gly Asn Leu Leu
35

<210> 13
<211> 24
<212> PRT
<213> artificial

<220>
<223> BCR/ABL breakpoint

<400> 13

Ile Val His Ser Ala Thr Gly Phe Gln Ser Ser Lys Ala Leu Gln Arg
1 5 10 15

Pro Val Ala Ser Asp Phe Glu Pro
20

<210> 14
<211> 44
<212> PRT
<213> artificial

<220>
<223> ubiquinatable peptide for BCR/ABL breakpoint

<400> 14

Arg Gly Lys Glu Gln Glu Met Ala Thr Ala Ala Ser Ser Gly Lys Lys
1 5 10 15

Lys Gly Gly Gly Ile Val His Ser Ala Thr Gly Phe Gln Ser Ser Lys
20 25 30

Ala Leu Gln Arg Pro Val Ala Ser Asp Phe Glu Pro
35 40